Global Academy for Medical Education develops educational CME programs for specialty and primary care physicians.

For news and views that matter to dermatology
Click here »

The Emerging Role of TNF Inhibition in Psoriasis and Psoriatric Arthritis

A supplement to Skin & Allergy News supported by an unrestricted educational grant from Wyeth and Amgen.
Highlights of presentations developed through physician interviews and from a continuing medical education satellite symposium.

•Contents
•Target Audience
•Educational Needs
•Learning Objectives
•Accreditation

Medical Education Library
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 12.

Contents

TNF Inhibitors in the Treatment of Psoriatic Arthritis: Results from Clinical Trials

Alice B. Gottlieb, MD, PhD
W.H. Conzen Chair in Clinical Pharmacology
Professor of Medicine
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School
New Brunswick
Clinical Grants: Wyeth and Amgen; Consultant: Wyeth and Amgen. Discusses the unlabeled and investigational use of etanercept for psoriasis.

The Role of TNF Inhibition in the Treatment of Psoriasis

Mark G. Lebwohl, MD
Chairman, Department of Dermatology
Mount Sinai School of Medicine
New York, N.Y.
Clinical Grants: Wyeth; Consultant: Wyeth. Discusses unlabeled and investigational use of etanercept for the treatment of psoriasis.

Experience with TNF Inhibitors: Five Years of Use in Rheumatic Disease

Marc D. Cohen, MD
Professor of Medicine
Mayo Medical School
Chairman, Division of Rheumatology
Department of Internal Medicine
Mayo Clinic
Jacksonville, FL
Research Grants: Wyeth, Amgen and Centocor; Consultant: Centocor, Amgen, Merck & Co., Pharmacia, Corp., Pfizer Inc. and Wyeth.

Immunobiology of Psoriasis and Pathogenic Roles for TNF

James G. Krueger, MD, PhD
Associate Professor
Medical Director
Laboratory for Investigative Dermatology
Rockefeller University
New York
Nothing to Disclose.
Target Audience

This activity has been developed for dermatologists and other health care professionals involved in the treatment of psoriasis and psoriatic arthritis.

Educational Needs

This activity is designed to fulfill the growing need among dermatologists to understand the potential role of TNF inhibitors in the treatment of psoriatic arthritis and psoriasis. The activity focuses on a variety of issues relative to this topic, including the role of TNF in the pathophysiology of psoriasis and psoriatic arthritis, experience with TNF inhibitors in rheumatic diseases, and findings of phase II and phase III studies of etanercept of psoriatic arthritis and psoriasis.

Learning Objectives

Upon completion of this program, participants should be able to:

• Understand how experience with TNF inhibitors in the rheumatology setting influences the use of etanercept in dermatology.

• Explain the rationale for TNF inhibition in the treatment of patients with immune-mediated inflammatory diseases such as psoriatic arthritis and psoriasis.

• Discuss the 5-year experience with efficacy and safety of TNF inhibitors in patients with rheumatic disease.

• Describe current concepts on the role of TNF in the pathophysiology of psoriasis and psoriatic arthritis.

Accreditation

The American Academy of Dermatology certifies that this educational activity has been recognized for 1 hour of AAD Category 1 credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award. Term of approval: August 2002-August 2003.